1
|
Muñoz D, Serrano MK, Hernandez ME, Haller R, Swanson T, Slaton JW, Sinha AA, Wilson MJ. Matrix metalloproteinase and heparin-stimulated serine proteinase activities in post-prostate massage urine of men with prostate cancer. Exp Mol Pathol 2017; 103:300-305. [DOI: 10.1016/j.yexmp.2017.11.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Accepted: 11/15/2017] [Indexed: 10/18/2022]
|
2
|
Slavin S, Yeh CR, Da J, Yu S, Miyamoto H, Messing EM, Guancial E, Yeh S. Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis 2013; 35:1301-9. [PMID: 24374826 DOI: 10.1093/carcin/bgt488] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The prostate cancer (PCa) microenvironment contains active stromal cells known as cancer-associated fibroblasts (CAF) that may play important roles in influencing tumor progression. Here we studied the role of CAF estrogen receptor alpha (ERα) and found that it could protect against PCa invasion. Immunohistochemistry on prostatectomy specimens showed that PCa patients with ERα-positive stroma had a significantly lower risk for biochemical recurrence. In vitro invasion assays further confirmed that the stromal ERα was able to reduce PCa cell invasion. Dissection of the molecular mechanism revealed that the CAF ERα could function through a CAF-epithelial interaction via selectively upregulating thrombospondin 2 (Thbs2) and downregulating matrix metalloproteinase 3 (MMP3) at the protein and messenger RNA levels. Chromatin immunoprecipitation assays further showed that ERα could bind to an estrogen response element on the promoter of Thbs2. Importantly, knockdown of Thbs2 led to increased MMP3 expression and interruption of the ERα mediated invasion suppression, providing further evidence of an ERα-Thbs2-MMP3 axis in CAF. In vivo studies using athymic nude mice injected with CWR22Rv1 (22Rv1) PCa epithelial cells and CAF cells ± ERα also confirmed that mice coimplanted with PCa cells and CAF ERα+ cells had less tumor foci in the pelvic lymph nodes, less metastases, and tumors showed less angiogenesis, MMP3, and MMP9 (an MMP3 downstream target) positive staining. Together, these data suggest that CAF ERα could play protective roles in suppressing PCa metastasis. Our results may lead to developing new and alternative therapeutic approaches to battle PCa via controlling ERα signaling in CAF.
Collapse
Affiliation(s)
- Spencer Slavin
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA
| | - Chiuan-Ren Yeh
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA
| | - Jun Da
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA, Department of Urology, Shanghai Jaotong University, Shanghai, China and
| | - Shengqiang Yu
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA
| | - Hiroshi Miyamoto
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA
| | - Edward M Messing
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA
| | - Elizabeth Guancial
- Departments of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Shuyuan Yeh
- Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA,
| |
Collapse
|
3
|
Justulin LA, Della-Coleta HHM, Taboga SR, Felisbino SL. Matrix metalloproteinase (MMP)-2 and MMP-9 activity and localization during ventral prostate atrophy and regrowth. ACTA ACUST UNITED AC 2010; 33:696-708. [PMID: 20059586 DOI: 10.1111/j.1365-2605.2009.01016.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Matrix metalloproteinses (MMPs) are enzymes involved in prostatic development, growth, disease-induced tissue remodelling and secretory fluid. Although the prostate function depends upon androgen regulation, the relationship between MMPs and androgen has not been well established. Here, we evaluated MMP-2 and MMP-9 gelatinolytic activity in association with tissue localization during ventral prostate atrophy and regrowth induced by testosterone replacement (TR). Adult male Wistar rats were divided into three experimental groups: control, castrated (CS) and TR 21 days after castration. Ventral prostate (VP) was excised at 3, 5, 7 and 21 days after castration in CS group, and at 3, 5, 7 and 10 days after TR (4 mg/kg/day) in TR group. The VP was dissected, weighed and processed for histology, immunohistochemistry, ultrastructure and zymography analyses. Castration elicited the typical parenchymal atrophy and stromal condensation. TR induced intense epithelial growth towards the stromal space to restore the prostate histoarchitecture. MMP-2 and MMP-9 immunostaining presented intense reaction in CS and TR groups, mainly in the epithelial and endothelial cells. After TR, a strong immunoreaction for MMP-2 was observed in the activated stromal fibroblasts. Zymography showed that MMP-2 and MMP-9 activity, mainly the active form, increased after castration. In contrast, TR induced an additional increase in MMP-2 activity, but not in MMP-9. In conclusion, the overall behaviour of MMP-2 and MMP-9 within the prostate under androgen handling is highly complex, as each glandular compartment and cell type is affected differently by the androgenic status. Prostate regrowth appears to involve a more effective participation of MMP-2 in both epithelial and stromal compartments, while MMP-9 plays a major role in the late prostate atrophy and early regrowth.
Collapse
Affiliation(s)
- L A Justulin
- Department of Cell Biology, Institute of Biology, University of Campinas (UNICAMP), Sao Paulo, Brazil.
| | | | | | | |
Collapse
|
4
|
Justulin Jr LA, Acquaro C, Carvalho RF, Silva MDP, Felisbino SL. Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. ACTA ACUST UNITED AC 2009; 33:489-99. [DOI: 10.1111/j.1365-2605.2009.00963.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Limaye AM, Desai KV, Chavalmane AK, Kondaiah P. Regulation of mRNAs encoding MMP-9 and MMP-2, and their inhibitors TIMP-1 and TIMP-2 by androgens in the rat ventral prostate. Mol Cell Endocrinol 2008; 294:10-8. [PMID: 18675881 DOI: 10.1016/j.mce.2008.07.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2006] [Revised: 05/24/2008] [Accepted: 07/07/2008] [Indexed: 11/27/2022]
Abstract
The relative activities of matrix metalloproteinases (MMPs) and their natural inhibitors (tissue inhibitors of matrix metalloproteinases, TIMPs) determine the extent of matrix degradation in any tissue. Their identification and characterization is key towards understanding remodeling of the prostate in the context of both castration induced atrophy and tumor invasion and metastasis. Although the expression of MMPs and TIMPs in prostate tumors has been reported, their regulation by androgens has not been studied. Here, we show that androgen ablation by castration increases the steady state mRNA levels of MMP-9, MMP-2, TIMP-1 and TIMP-2. Blockade of the androgen receptor using flutamide, however, has differential effects on the steady state mRNA expressions of these genes. We also show that both castration and flutamide treatment cause enhanced expression of a high molecular weight gelatinolytic activity in the rat ventral prostate (RVP). Actinomycin D does not affect the increase in steady state mRNA levels of MMP-9 and TIMP-1. Furthermore we show that actinomycin D alone enhances the steady state mRNA and protein levels of these genes. Using RNA gel shift assay with 3'-UTR of TIMP-1, we show that an RNA binding protein is induced following castration. Taken together our data suggest that the induction of MMP-2, MMP-9, TIMP-1 and TIMP-2 mRNAs post-castration could be at least in part due to post-transcriptional stabilization.
Collapse
Affiliation(s)
- Anil M Limaye
- Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore 560012, India
| | | | | | | |
Collapse
|
6
|
Chen KC, Hsieh CL, Peng CC, Hsieh-Li HM, Chiang HS, Huang KD, Peng RY. Brain derived metastatic prostate cancer DU-145 cells are effectively inhibited in vitro by guava (Psidium gujava L.) leaf extracts. Nutr Cancer 2007; 58:93-106. [PMID: 17571972 DOI: 10.1080/01635580701308240] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The aqueous extract of Psidium guajava L. (PE) inhibited the cancer cell DU-145 in a dose- and time-dependent manner. At 1.0 mg/mL, PE reduced the viability of PCa DU-145 (the androgen independent PCa cells) to 36.1 and 3.59%, respectively after 48 h and 72 h of incubations. The absolute cell viability suppressing capability (VSC)(AC) could reach 262.5 cells-mL-h/mg on exposure to PE for 72 h, corresponding to the safe ranges, i.e. the percent viability suppressing rates (PVSR) of 2.72 and 2.41 folds for DU-145 comparing to PZ-HPV-7 cells when treated with PE at 0.5 and 1.0 mg/mL respectively for 72 h. In addition, the colony forming capability of DU-145 cells was apparently lowered. The suppressing rates of which reached 8.09 and 5.96 colony/mg/day for D-145 and PZ-HPV-7 cells, respectively within the concentration range of PE at 0.1 asymptotically equal to 0.25 mg/mL. Cell cycle arrests at G0/G1 phase in both cells were observed by TUNEL assay and flow cytometric analysis, yet more prominently evident in DU-145. In addition, suppression of the matrix metalloproteinases MMP-2 and MMP-9, and the upregulation of active caspase-3 at 0.10 to 1.0 mg/mL in DU-145 were also effected in a dose-dependent manner by PE at 0.25 to 1.0 mg/mL, implicating a potent anti-metastasis power of PE. Conclusively, we ascribe the anticancer activity of PE to its extraordinarily high polyphenolic (165.61 +/- 10.39 mg/g) and flavonoid (82.85 +/- 0.22 mg/g) contents. Furthermore, PE might be useful for treatment of brain derived metastatic cancers such as DU-145, acting simultaneously as both a chemopreventive and a chemotherapeutic.
Collapse
Affiliation(s)
- Kuan-Chou Chen
- Graduate Institute of Medical Sciences, College of Medicine, Department of Urology, Taipei Medical University Hospital, No. 250 Wu-Xin Street, Taipei 116, Taiwan
| | | | | | | | | | | | | |
Collapse
|
7
|
Bailey TR, Paulsen DB, Sehgal I, Hosgood G. Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs. Am J Vet Res 2006; 67:1628-34. [PMID: 16948613 DOI: 10.2460/ajvr.67.9.1628] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine distribution of urokinase plasminogen activator-like protein and urokinase plasminogen activator receptor-like protein in urinary tract tissues of healthy dogs. ANIMALS 11 healthy dogs. PROCEDURES Necropsy specimens from kidney, ureter, bladder, urethra, prostate, and testis were obtained from 4 sexually intact female dogs, 5 sexually intact males, and 2 castrated males; dogs ranged in age from juvenile to adult. Urokinase plasminogen activator-like protein and urokinase plasminogen activator receptor-like protein in tissue lysates from kidney, prostate, and testis were identified by use of SDS-PAGE, western blot analysis, and immunoprecipitation. Urokinase plasminogen activator-like protein and urokinase plasminogen activator receptor-like protein in kidney, ureter, urinary bladder, urethra, prostate, and testis were identified by use of immunohistochemical staining of tissue sections. RESULTS Urokinase plasminogen activator-like protein and urokinase plasminogen activator receptor-like protein in the molecular-weight range published for urokinase and urokinase receptor (53 and 33 kd for urokinase and 60 to 65 kd for urokinase receptor) were identified. Distribution of the proteins identified by use of immunohistochemical staining was comparable with published information for humans and mice for the urinary tract. Staining of these proteins was detected in more tissue types than reported in healthy humans. CONCLUSIONS AND CLINICAL RELEVANCE Urokinase plasminogen activator-like protein and urokinase plasminogen activator receptor-like protein were detected in the urinary tract of healthy dogs. This information is important for further evaluation of the functions of urokinase and urokinase receptor in the canine urinary tract and the pathophysiologic features of urinary tract disease.
Collapse
Affiliation(s)
- Trina R Bailey
- Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| | | | | | | |
Collapse
|
8
|
Diaw L, Roth M, Schwinn DA, d'Alelio ME, Green LJ, Tangrea JA. Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention. In Vitro Cell Dev Biol Anim 2006; 41:142-8. [PMID: 16153146 DOI: 10.1290/0412079.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
An immortalized human prostate stromal cell line (PS30) was previously established using recombinant retrovirus encoding human papillomavirus 16 gene products. In this study, we further characterize this stromal cell line for its potential use in a stromal-epithelial coculture model for prostate cancer prevention. Using reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, and immunocytochemistry, we examined expression of androgen receptor (AR), vitamin D receptor (VDR), prostate-specific antigen (PSA), transforming growth factor-beta (TGF-beta), and insulin-like growth factors (IGF) families and their receptors, metalloproteinases (MMP) MMP-2 and MMP-9, as well as the cells' ability to respond to the synthetic androgen R1881. The PS30 stromal cells do not express PSA, confirming their stromal origin. They are positive for both AR messenger ribonucleic acid (mRNA) and protein; however, they do not respond to growth stimulation by the synthetic androgen R1881. The PS30 cells express mRNA for VDR, TGF-betas, IGFs and their receptors, as well as the MMPs. Moreover, they produce significant amounts of TGF-beta1, TGF-beta2, IGFBP-3, and MMP-2 proteins. Our observations confirm the use of PS30 for the study of stromal-epithelial interactions in the modulation of prostate carcinogenesis.
Collapse
Affiliation(s)
- Lena Diaw
- SAIC-Frederick Inc., National Cancer Institute/Advanced Technology Center, Bethesda, Maryland, USA.
| | | | | | | | | | | |
Collapse
|
9
|
Wilson MJ, Jiang A, Wiehr C, Wang X, Sinha AA, Pei D. Limited processing of pro-matrix metalloprotease-2 (gelatinase A) overexpressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1. ACTA ACUST UNITED AC 2004; 25:274-85. [PMID: 14760014 DOI: 10.1002/j.1939-4640.2004.tb02788.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The expression and activation of matrix metalloproteinases (MMPs) by tumor cells is correlated with progression to invasive and metastatic status. The purpose of this study was to examine the role of increased MMP-2 (gelatinase A) expression in prostate cancer progression utilizing human prostate PC-3 cancer cells that overexpress MMP-2 using gene transfection. PC-3 cells were transfected with pCR-3 vector only and pCR-3 MMP-2 plasmids employing the LipofectAMINE method, and stable transfectants were selected with G418. The expression of MMP-2, tissue inhibitor of metalloproteinase-2 (TIMP-2), and membrane-type MMP 1 (MT1-MMP) in PC-3 parental and transfected cells under serum-free conditions was determined by zymography, immunoblotting, immunofluorescent microscopy, Northern blotting, and/or reverse transcriptase-polymerase chain reaction (RT-PCR). MMP-2 transfected cells produced primarily the proenzyme form of MMP-2; the parental and vector control transfected PC-3 cells did not express any MMP-2 that was detectable by the methods we employed. Treatment of PC-3 MMP-2 transfected cells with Concanavalin A (Con A), in contrast to HT-1080 cells, processed only a small amount of the secreted 72-kd proenzyme to a 62-kd intermediate and a cell-associated 59-kd active form. The low level of secreted pro-MMP-2 processing induced by Con A was inhibited by serine protease inhibitors and was unaffected by cyclic adenosine monophosphate (cAMP). Immunoblotting showed that these cells produced abundant TIMP-2 and lower amounts of MT1-MMP in comparison with Con A-responding HT-1080 cells. HT-1080 cells respond to Con A by translocating MT1-MMP from intracellular localization sites to the plasma membrane, an effect not observed in PC-3 cells. The molecular basis for the low level of processing of pro-MMP-2 by PC-3 cells may be due to an overabundance of TIMP-2 and/or a low level of cell surface active MT1-MMP.
Collapse
Affiliation(s)
- Michael J Wilson
- Minneapolis VA Medical Center, and Department of Laboratory Medicine and Pathology, and Minnesoata Cancer Center, University of Minnesota, Minneapolis, USA.
| | | | | | | | | | | |
Collapse
|
10
|
Aalinkeel R, Nair MPN, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004; 64:5311-21. [PMID: 15289337 DOI: 10.1158/0008-5472.can-2506-2] [Citation(s) in RCA: 123] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We hypothesize that expression of proangiogenic genes correlates with the metastatic potential of prostate cancer cells. LNCaP, DU-145, and PC-3 are prostate cancer cell lines with low, moderate, and high metastatic potential, respectively, as we demonstrated by their capacity to invade an extracellular matrix, an established tumor invasion assay. The constitutive gene expression of the proangiogenic factors, vascular endothelial growth factor, intercellular adhesion molecule-1, interleukin-8, and transforming growth factor-beta2, was significantly greater in the more metastatic DU-145 and PC-3 cells as compared with LNCaP cells. Matrix metalloproteinase (MMP)-9 is thought to contribute to the invasive phenotype of tumor cells. PC-3 cells showed increased expression of MMP-9 and membrane type 4-MMP as compared with LNCaP and DU-145. Tissue inhibitors of metalloproteinase 1 and 4 gene expression were elevated in DU-145 and PC-3 cells, but paradoxically, LNCaP cells had undetectable levels of these genes. We transfected and overexpressed MMP-9 in poorly metastatic LNCaP cells and measured their invasive activity. Transient expression of human MMP-9 in LNCaP cells produced a 3-5-fold increase in MMP-9 activity with a comparable increase in invasiveness. Antisense ablation of the expression of MMP-9 in DU-145 and PC-3 cells produced concomitant inhibition of the gene expression of the proangiogenic factors, vascular endothelial growth factor, and intercellular adhesion molecule-1 (ICAM-1). Treatment of DU-145 and PC-3 cells with a selective chemical inhibitor of MMP-9 proteinase activity also inhibited their invasive activity. These results support our hypothesis that metastatic potential of prostate cancer cells correlates with expression of proangiogenic factors.
Collapse
Affiliation(s)
- Ravikumar Aalinkeel
- Department of Medicine, Division of Allergy, Immunology and Rheumatology, State University of New York at Buffalo, 100 High Street, Buffalo, NY 14203, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002; 191:208-16. [PMID: 12064464 DOI: 10.1002/jcp.10092] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The production of matrix metalloproteinases (MMPs) by prostatic epithelial and/or neighboring stromal cells is considered to be a property that gives cells the capability to penetrate extracellular matrix barriers in normal or neoplastic growth. In order to examine the role of MMPs in the prostate, we evaluated the expression of MMP-2 and -9 and the tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2 in primary cultures of prostatic stromal and epithelial cells. These cells were isolated from normal tissues of the different zones of the prostate, from benign prostatic hyperplasia (BPH) and from cancer. Stromal cells, regardless of tissue of origin, secreted the 72-kDa proenzyme form of MMP-2, whereas conditioned media (CM) from epithelial cells demonstrated little/no pro-MMP-2 as examined by zymography. Either type of cell did not secrete MMP-9. RT-PCR evaluation showed stromal cells expressed transcripts for MMP-2, but not for MMP-9. Transcripts for MMP-9 were detected in epithelial cells, although no MMP-9 activity was detected in their CM. Treatment of stromal cells with 1 or 10 ng/ml of transforming growth factor-beta (TGF-beta) moderately increased secretion of pro-MMP-2 protein with little change in MMP-2 RNA. However, treatment of epithelial cells with TGF-beta induced expression and secretion of both MMP-2 and-9. The effect of TGF-beta on expression of MMPs by epithelial cells was not duplicated or affected by treatment with insulin-like growth factor (IGF)-1, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), or basic fibroblast growth factor (bFGF). Stromal cells expressed transcripts of both TIMP-1 and -2. Epithelial cells expressed TIMP-1, but little TIMP-2. TGF-beta did not regulate the expression of TIMP-1 or -2 in either stromal or epithelial cells. Our results suggest that the elevated levels of MMP-2 and -9 observed in prostate development and cancer may be due to the elevated TGF-beta associated with these tissues.
Collapse
|
12
|
Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA, Lichtinghagen R. Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines. Prostate 2002; 50:38-45. [PMID: 11757034 DOI: 10.1002/pros.10030] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND The aim was to investigate the expression of matrix metalloproteinases (MMPs), membrane type MMPs (MT-MMPs), and their inhibitors (TIMPs) in human primary cultured prostatic cells and malignant prostate cell lines. METHODS Reverse transcription-polymerase chain reaction-based measurements of the mRNA levels of MMP-2, MMP-7, MT1-MMP, MT3-MMP, TIMP-1, and TIMP-2 in relation to the house-keeping gene glyceraldehyde phosphate dehydrogenase were performed in cancerous and non-cancerous prostatic tissue samples, in primary cell cultures of epithelial cells, in both fibroblasts, and smooth-muscle cells as stromal cells, and in the human malignant prostatic cell lines DU-145, LNCaP, and PC-3. RESULTS MMP-2 was mainly expressed in the stromal cells and MMP-7 showed their highest values in the epithelial cells. MT1-MMP, MT3-MMP, TIMP-1, and TIMP-2 were found both in the stromal and in the epithelial cells, but there were some differences between the expressions in fibroblasts and smooth-muscle cells. Different expressions were also observed between the cells deriving from the primary cell cultures, the benign cell line BPH-1, and the malignant cell lines LNCaP, D-145, and PC-3. CONCLUSIONS These exemplary results concerning different expressions of MMPs and TIMPs in cells from prostatic tissue suggest that a better insight into changes observed in prostatic tissue needs studies on cells cultured from the tissue.
Collapse
Affiliation(s)
- Ju Zhang
- Department of Urology, University Hospital Charité, Humboldt University Berlin, Berlin, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Elfman F, Bok R, Conn M, Shuman M, Cunha G. Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate. Differentiation 2001; 69:108-20. [PMID: 11798065 DOI: 10.1046/j.1432-0436.2001.690205.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The plasma membrane urokinase plasminogen activator receptor (uPAR) localizes and enhances activation of pro-uPA. Active uPA, in turn, promotes increased degradation of the extracellular matrix (ECM) by activation of plasminogen. uPAR binds to ECM molecules and integrins, which can affect cellular adhesion, signal transduction, and gene regulation. The current study examines the expression and function of uPAR in developing rat ventral prostates (VPs). We report that newborn VPs express uPAR mRNA and protein. In addition, the function of uPAR-bound uPA during in vitro prostatic development was studied by adding recombinant peptide competitive inhibitors of uPA-uPAR binding. Newborn VP explants were cultured in serum-free media for one week with 10(-8) M testosterone plus chimeric peptides containing a human immunoglobulin G Fc domain and either human uPA amino acids 1-138 (hu-uPA 1-138) as a control or mouse uPA amino acids 1-138 (mo-uPA 1-138) or 1-48 (mo-uPA 1-48). Hu-uPA 1-138-treated VPs underwent normal ductal branching morphogenesis and tissue differentiation. In contrast, VPs treated with mo-uPA 1-138 or mo-uPA 1-48 displayed a dose-dependent perturbation of ductal branching. Differentiation of both epithelial and mesenchymal tissues was also impaired. Mo-uPA 1-48-treated VPs contained significantly more apoptotic cells. These observations suggest that disruption of uPA binding to uPAR results in a retardation of the development of newborn VPs.
Collapse
Affiliation(s)
- F Elfman
- Department of Anatomy, University of California, San Francisco 94143, USA
| | | | | | | | | |
Collapse
|
14
|
Wilson MJ, Casey C, Woodson M, Sinha AA. Reverse zymography studies of protease inhibitors in the secretions of different lobes of rat prostate. ARCHIVES OF ANDROLOGY 1999; 42:109-18. [PMID: 10101578 DOI: 10.1080/014850199262959] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
The purpose of this study was to determine whether protease inhibitors were a constituent of secretions from the different lobes of the rat prostate. A reverse zymography method was used employing gelatin substrate-SDS-polyacrylamide gel electrophoresis to detect inhibitors of trypsin in secretions of the ventral, lateral, and dorsal prostate lobes of the Sprague-Dawley rat. Inhibitors of approximately 34 and 63 kDa were detected in ventral prostate secretion and of about 63 and 73 kDa were found in lateral lobe secretion. However, no inhibitor activities were detected in secretions of the dorsal lobe. The protease inhibitors of ventral prostate secretion were partially purified by preparatory isolectric focusing and SDS-polyacrylamide gel electrophoresis. The 34-kDa (pI 5.6-6.4) inhibitor had a higher activity against trypsin, whereas the 63-kDa (pI 6.4-7.0) inhibitor was more active against chymotrypsin. The rat prostate appears to have a lobe-specific distribution of secretory serine protease inhibitors.
Collapse
Affiliation(s)
- M J Wilson
- VA Medical Center, Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, University of Minnesota, Minneapolis 55417, USA
| | | | | | | |
Collapse
|
15
|
Friedrich B, Jung K, Lein M, Türk I, Rudolph B, Hampel G, Schnorr D, Loening SA. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 1999; 35:138-44. [PMID: 10211102 DOI: 10.1016/s0959-8049(98)00273-1] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Elevated activities of cysteine proteinases, the cathepsins B, H, L (CB, CH, CL) and diminished cysteine protease inhibitors (CPI) have been demonstrated in a variety of tumours and have been suggested to contribute to invasion and metastasis. The situation for prostate cancer is still unknown. In this study, using fluorimetric assays, the catalytic activities of CB, CH, CL were measured in prostatic tissue samples after radical prostatectomy, adenomectomy, transurethral resection of the prostate, in cell cultures grown from cancerous and non-cancerous parts of human prostate after prostatectomy and in the cell lines LNCaP, DU 145 and PC 3. CPIs were determined using heat activation before testing their inhibitory activity against purified CB. Comparing matched pairs of normal and cancerous tissue samples from the prostate, significantly decreased levels of CB, CL in malignant parts of the prostate were found. In contrast, primary cell cultures from cancerous samples showed elevated levels of CB, CH, CL and increased ratios of cathepsins to CPI compared with cell cultures from normal prostate. Established cell lines showed a similar distribution pattern of each cathepsin, DU 145 containing the highest levels, followed by LNCaP and PC 3. Our results suggest that elevated cathepsin levels and consequently increased ratios of cathepsins to CPI in primary cell cultures from cancerous versus non-cancerous parts of the prostate may be indicative of a cellular proteolytic imbalance in prostatic cancer cells. In this respect, primary cell culture experiments should be preferred to determinations in tissue samples.
Collapse
Affiliation(s)
- B Friedrich
- Department of Urology, University Hospital Charité, Humboldt University Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Chang WY, Wilson MJ, Birch L, Prins GS. Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate. Endocrinology 1999; 140:405-15. [PMID: 9886852 DOI: 10.1210/endo.140.1.6401] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The purpose of this study was to examine whether changes in extracellular matrix (ECM) molecules are associated with the growth inhibition and differentiation defects of the prostate gland following neonatal exposure to estradiol. Using immunocytochemistry (ICC), laminin and collagen IV were localized to the basement membrane (BM) as well to the basal lamina of the periductal smooth muscle of the control developing prostates. In contrast, fibronectin and collagen III were localized throughout the stromal ECM. Exposure to neonatal estrogen altered the staining profile for specific ECM molecules. In the estrogenized rats, a thick layer of cells negative for laminin and collagen IV was observed adjacent to the BM. Electron microscopy and ICC for alpha-actin, fibronectin, and vimentin identified this multicellular layer of periductal cells as differentiated fibroblasts. Peripheral to these fibroblasts, actin-positive smooth muscle formed a second layer of periductal stromal cells. PCNA labeling showed that estrogen exposure increased the fibroblast proliferation. Because many periductal fibroblasts were positive for estrogen receptor alpha (ER alpha) in estrogenized rats, a direct effect of estradiol on their proliferation is suggested. Gelatinolytic gels revealed that estrogen exposure did not alter the activity of matrix metalloproteinases associated with tissue remodeling during prostate morphogenesis. However, the periductal fibroblast layer in estrogenized prostates was devoid of urokinase- and tissue-plasminogen activator, which may potentially alter the localized proteolysis involved in matrix remodeling. It is proposed that proliferation of a multicellular layer of periductal fibroblasts in estrogenized prostates results in a physical barrier that constrains branching morphogenesis and blocks paracrine communications between smooth muscle and epithelial cells which normally regulate differentiation.
Collapse
Affiliation(s)
- W Y Chang
- Department of Urology, University of Illinois College of Medicine, Chicago 60612, USA
| | | | | | | |
Collapse
|
17
|
PROSTATE SPECIFIC ORIGIN OF DIPEPTIDYLPEPTIDASE IV (CD-26) IN HUMAN SEMINAL PLASMA. J Urol 1998. [DOI: 10.1097/00005392-199811000-00081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
WILSON MICHAELJ, RUHLAND AMYR, PRYOR JONL, ERCOLE CESAR, SINHA AKHOURIA, HENSLEIGH HUGH, KAYE KEITHW, DAWKINS HUGHJ, WASSERMAN NEILF, REDDY PRATAP, AHMED KHALIL. PROSTATE SPECIFIC ORIGIN OF DIPEPTIDYLPEPTIDASE IV (CD-26) IN HUMAN SEMINAL PLASMA. J Urol 1998. [DOI: 10.1016/s0022-5347(01)62441-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- MICHAEL J. WILSON
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - AMY R. RUHLAND
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - JON L. PRYOR
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - CESAR ERCOLE
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - AKHOURI A. SINHA
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - HUGH HENSLEIGH
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - KEITH W. KAYE
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - HUGH J.S. DAWKINS
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - NEIL F. WASSERMAN
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - PRATAP REDDY
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| | - KHALIL AHMED
- From the Minneapolis VA Medical Center, University of Minnesota Cancer Center, and Departments of Laboratory Medicine and Pathology, Urologic Surgery, Cell Biology and Neuroanatomy, Obstetrics and Gynecology, Genetics and Cell Biology, and Radiology, University of Minnesota, Minneapolis, the Department of Urology, St. Paul Ramsey Medical Center, St. Paul, Minnesota, and the Urologic Research Centre, University of Western Australia, Nedlands, Australia
| |
Collapse
|
19
|
Larsen M, Ressler SJ, Lu B, Gerdes MJ, McBride L, Dang TD, Rowley DR. Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J Biol Chem 1998; 273:4574-84. [PMID: 9468514 DOI: 10.1074/jbc.273.8.4574] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We previously reported the purification of ps20 (Rowley, D. R., Dang, T. D., Larsen, M., Gerdes, M. J., McBride, L., and Lu, B. (1995) J. Biol. Chem. 270, 22058-22065), a urogenital sinus mesenchymal cell secreted protein having growth-inhibitory properties. We report here cloning of the 1.03-kilobase rat ps20 cDNA clone from the PS-1 (adult rat prostate smooth muscle) cDNA library. Partial clones were obtained by nested polymerase chain reaction with degenerate primers, and full-length ps20 cDNA clones were isolated by plaque hybridization. Sequence analysis revealed that ps20 protein contains a WAP-type "four-disulfide core" motif and is a novel member of the WAP signature protein family composed primarily of secreted serine protease inhibitors. Native ps20 immunoprecipitated from smooth muscle cells and recombinant ps20 both resolved on SDS-polyacrylamide gel electrophoresis with apparent molecular mass of 27-29 kDa under reducing conditions and 21-23 kDa under non-reducing conditions, respectively. Stable ps20-transfectant COS-7 cell lines secreted ps20 and were growth-inhibited relative to mock transfectants. In addition, COS-7 and prostate carcinoma PC-3 cells were growth-inhibited by bacterially expressed ps20. Northern analysis indicated differential expression by tissue with highest expression in the heart. Immunohistochemical localization of ps20 protein showed cell-specific expression by both visceral and vascular smooth muscle in all tissues, including the prostate gland. These results indicate ps20 is a novel growth-regulatory member of the WAP signature family expressed by smooth muscle cells.
Collapse
Affiliation(s)
- M Larsen
- Cell and Molecular Biology Program, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | |
Collapse
|
20
|
Jung K, Lein M, Ulbrich N, Rudolph B, Henke W, Schnorr D, Loening SA. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects. Prostate 1998; 34:130-6. [PMID: 9465944 DOI: 10.1002/(sici)1097-0045(19980201)34:2<130::aid-pros8>3.0.co;2-o] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND The balance between matrix metalloproteinases (MMP) and the tissue inhibitors of metalloproteinases (TIMP) has been seen as important during tumor invasion and progression. The determination of these components needs a special strategy of tissue preparation. This analytical problem has not been considered for prostatic tissue. METHODS We adapted an extraction method consisting of two extraction steps with 0.25% Triton X-100/CaCl2 solution and two heat extraction steps at 60 degrees C for 4 min. This combination allowed a complete extraction of MMP (measured as enzyme activity) and TIMP-1 (measured with an ELISA test) from cancerous and normal prostatic tissue samples. RESULTS The median values for cancerous vs. normal MMPs (50.8 mU/g wet tissue and 1,580 mU/g protein vs. 88.8 and 2,497) and TIMP-1 (4.49 micrograms/g wet tissue and 96.7 micrograms/g protein vs. 12.4 and 237.8) were significantly lower, whereas the respective ratios for MMP/ TIMP-1 (11.1 vs. 4.0 on wet weight and 15.5 vs. 5.3 on protein basis) were significantly higher. CONCLUSIONS An optimized extraction procedure was elaborated for determining MMPs and TIMP-1 in prostatic tissue samples. The increased ratio of MMP/TIMP-1 can be interpreted as an indicator of the imbalance between MMP and TIMP, characteristic of prostate carcinoma tissue.
Collapse
Affiliation(s)
- K Jung
- Department of Urology, University Hospital Charité, Humboldt University, Berlin, Germany.
| | | | | | | | | | | | | |
Collapse
|
21
|
Quax PH, de Bart AC, Schalken JA, Verheijen JH. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. Prostate 1997; 32:196-204. [PMID: 9254899 DOI: 10.1002/(sici)1097-0045(19970801)32:3<196::aid-pros6>3.0.co;2-j] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The plasminogen activation (PA) and metalloproteinase (MMP) system are involved in tumor cell migration and invasion. METHODS The proteolytic activity of cell lines originating from the rat Dunning R-3327 prostate tumor was analyzed by measuring in vitro extracellular matrix degradation, enzyme activity, and mRNA levels of enzymes, inhibitors, and receptors, and compared with their known metastatic behavior in vivo. RESULTS Only the highly metastatic sublines AT-3, MATLu, and MATLyLu showed a high extracellular matrix degradation mediated by urokinase-type plasminogen activator (u-PA). Relatively high levels of u-PA were present in the aggressive cell lines. u-PA receptor mRNA was produced in all cells, and all but AT-1 produced LDL-receptor-related-protein (LRP) mRNA. t-PA mRNA was only found in HIF and MATLu. In gelatin, zymography lysis was observed at 72 kD and 74-76 kD in MATLu and MATLyLu cells, respectively. MMP-2 mRNA was present in all cell lines except AT-1 and AT-2, and MMP-3 mRNA was present in AT-2, AT-3, and MATLu. CONCLUSIONS These in vitro experiments show that in different rat prostate cancer sublines, proteolytic activity and u-PA-mediated extracellular matrix degradation correlate with their known metastatic behavior in vivo.
Collapse
MESH Headings
- Analysis of Variance
- Animals
- Blotting, Northern
- DNA, Complementary/analysis
- DNA, Complementary/genetics
- Extracellular Matrix/chemistry
- Extracellular Matrix/enzymology
- Extracellular Matrix/metabolism
- Gene Expression Regulation, Neoplastic
- In Vitro Techniques
- Male
- Metalloendopeptidases/analysis
- Metalloendopeptidases/biosynthesis
- Metalloendopeptidases/genetics
- Neoplasm Metastasis/pathology
- Plasminogen Activator Inhibitor 1/analysis
- Plasminogen Activator Inhibitor 1/genetics
- Plasminogen Activator Inhibitor 1/metabolism
- Plasminogen Activators/analysis
- Plasminogen Activators/biosynthesis
- Plasminogen Activators/genetics
- Prostate/chemistry
- Prostate/metabolism
- Prostate/pathology
- Prostatic Neoplasms/chemistry
- Prostatic Neoplasms/metabolism
- Prostatic Neoplasms/pathology
- RNA, Messenger/analysis
- RNA, Messenger/genetics
- Rats
- Rats, Inbred Strains
- Receptors, Cell Surface/analysis
- Receptors, Cell Surface/genetics
- Receptors, Urokinase Plasminogen Activator
- Tissue Plasminogen Activator/analysis
- Tissue Plasminogen Activator/genetics
- Tissue Plasminogen Activator/metabolism
- Tumor Cells, Cultured
- Urokinase-Type Plasminogen Activator/analysis
- Urokinase-Type Plasminogen Activator/genetics
- Urokinase-Type Plasminogen Activator/metabolism
Collapse
Affiliation(s)
- P H Quax
- Gaubius Laboratory TNO-PG, Leiden, The Netherlands.
| | | | | | | |
Collapse
|
22
|
Bryś M, Nawrocka AD, Miekoś E, Zydek C, Foksiński M, Barecki A, Krajewska WM. Zinc and cadmium analysis in human prostate neoplasms. Biol Trace Elem Res 1997; 59:145-52. [PMID: 9522056 DOI: 10.1007/bf02783239] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The objective of this study was to test the hypothesis that prostatic cancer is associated with the changes of zinc (Zn) and cadmium (Cd) concentration. Normal prostate, benign prostatic hyperplasia (BPH), and prostatic carcinoma (PCA) were analyzed for Zn and Cd by atomic absorption spectrometry. Cd level was measured using a graphite furnace and Zn level was measured by flame mode. Metal content was assessed in whole tissues and in nuclear, plasma membrane, and cytosolic fractions. An increase of Zn content in BPH, but a decrease in PCA as compared to normal tissue, was observed. Cd concentration appeared to be higher in BPH and PCA than in normal tissue. No correlation between Zn and Cd level was found in BPH specimens obtained from the same patients. Probability values of p < or = 0.05 were considered to indicate significant differences. Obtained results seem to support the hypothesis of Cd carcinogenicity and preventing function of Zn in prostatic cancer. Plasma membrane fraction corresponding to lysosomal, mitochondrial, and microsomal subcellular compartments are probably critical in Zn and Cd participation in human prostate neoplasms.
Collapse
Affiliation(s)
- M Bryś
- Department of Cytobiochemistry, University of Lódź, Poland
| | | | | | | | | | | | | |
Collapse
|
23
|
Wilson MJ, Ludowese C, Sinha AA, Estensen RD. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. Prostate 1996; 28:239-50. [PMID: 8602400 DOI: 10.1002/(sici)1097-0045(199604)28:4<239::aid-pros5>3.0.co;2-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The involution of the prostate gland after castration is an active process which requires the induction of new proteins. The plasminogen activator urokinase has been proposed to be a gene repressed by androgen which is activated upon castration and thus participating in the atrophy of the gland. However, urokinase is secreted by the ventral lobe of the rat prostate and this should be positively affected by androgens. The purpose of this study was to examine further the effects of castration upon plasminogen activator (PA) activities in the rat prostate and to determine possible explanations to this apparent dilemma. Castration of young sexually mature adult rats resulted in a substantial increase in PA activities at 4 days after castration in the ventral prostate, but then the activities returned to within the range of untreated animals with a longer duration of castration. Urokinase was the predominant molecular form of PA in the normal ventral prostate and it was the molecular form increased after castration; based upon its sensitivity to amiloride and its molecular size determined in zymograms. In contrast to the effect of castration, there was no increase in PA activities in the ventral prostate with treatment of rats with the antiandrogen flutamide, but rather a decrease when specific activity was expressed per unit DNA. In addition, the effect of castration was specific for the ventral lobe for there was no change in the PA activity in the dorsolateral prostate after androgen ablation. The diminished PA activities in the ventral prostates of rats castrated for 7 days or longer appeared to be due at least in part to an increase in plasminogen activator inhibitor type-1 (PAI-1). Immunoreactive PAI-1 was found predominantly in high molecular weight forms which indicates that the inhibitor was complexed with PA. Daily treatment of rats upon castration with agents known to retard the rate of regression of the involuting prostate gave dichotomous results. Hydrocortisone prevented the increase in PA activity, whereas treatment with actinomycin D, an inhibitor of RNA synthesis, not only did not prevent an increase in PA activity, but actually produced a superinduction in PA activity at 4 days orchiectomy. These data may be interpreted to mean that hydrocortisone stimulated PAI activity and that actinomycin D treatment blocked its induction. However, the actinomycin D data may also indicate that an increase in urokinase protein and mRNA after castration may result from some mechanism to conserve these molecules suggesting that this inhibitor of RNA synthesis prevented the transcription of messages for proteins involved in the degradation of urokinase message.
Collapse
Affiliation(s)
- M J Wilson
- VA Medical Center, Minneapolis, MN 55417, USA
| | | | | | | |
Collapse
|
24
|
Wilson MJ, Norris H, Woodson M, Sinha AA. Effect of castration on metalloprotease activities in the lateral, dorsal, and anterior lobes of the rat prostate. ARCHIVES OF ANDROLOGY 1995; 35:119-25. [PMID: 8579472 DOI: 10.3109/01485019508987862] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Several proteolytic enzymes are involved in mediating the regression of the prostate gland following castration. A previous study showed that plasminogen activator activities are elevated only in the ventral lobe by castration in the rat. Since matrix metalloproteases represent a different class of protease that degrade extracellular matrix, this study examined their activities in the lateral, dorsal, and anterior lobes of the rat in response to androgen deprivation. The results indicate that, in contrast to plasminogen activators, metalloprotease activities are increased in the lateral, dorsal, and anterior lobes following orchiectomy. This suggests that differences in regulation of certain proteases by androgens may occur in individual prostatic lobes.
Collapse
Affiliation(s)
- M J Wilson
- VA Medical Center, Minneapolis, Minnesota, USA
| | | | | | | |
Collapse
|